Advertisement

Experimental Basis for Optimal Regimnes of Hyperthermic Peritoneal Chemotherapy

  • Natalia Yu. Anisimova
  • Irina Zh. Zhubina
  • Fedor V. Donenko
  • Julia I. Dolzhikova
  • Antonina V. Kshnaykina
  • Mikhail V. Kiselevskiy
Chapter

Abstract

Temperature exposure reliably inhibits tumor cell potential for proliferation at the temperature of not less than 43 °C only. Temperature regimens recommended for clinical treatment (40–42 °С) have no significant impact on the viability of tumor cells. Tumor growth arrest in murine models was observed only in case of preliminary warming of inoculated cells at a temperature more than 42 °С. Heating tumor cells up to 39 °С and their incubation with anticancer drugs in the mean-effective concentrations enhanced tumor cell sensitivity towards cytotoxic action of activated lymphocytes.

Keywords

Hyperthermia Anticancer drugs Cytotoxicity Tumor cells Effectors of antitumor immunity 

References

  1. 1.
    Elias D, Raynard B, Boige V, Laplanche A, Estphan G, Malka D, Pocard M (2005) Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 90:220–225CrossRefGoogle Scholar
  2. 2.
    Baronzio G (2012) Hyperthermia and intracavitary chemotherapy in prevention and treatment of malignant effusions. In: Kiselevsky MV (ed) Malignant effusions: pleuritis, ascites, pericardites. Springer, Dordrecht/New York, pp 123–150CrossRefGoogle Scholar
  3. 3.
    Glehen O, Cotte E, Brigand C, Arvieux C, Sayag-Beaujard AC, FN G (2006) Therapeutic innovations in the management of peritoneal carcinomatosis from digestive origin: Cytoreductive surgery and intraperitoneal chemotherapy. Rev Med Int 27:382–391CrossRefGoogle Scholar
  4. 4.
    Smeenk RM, Verwaal VJ, Zoetmulder FA (2006) Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei – A report of 103 procedures. Eur J Surg Oncol 32:186–190CrossRefGoogle Scholar
  5. 5.
    Bevanda M, Orsolic N, Basic I, Vukojevic K, Benkovic V, Horvat Knezevic A, Lisicic D, Dikic D et al (2009) Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2. Int J Hyperth 25(2):132–140CrossRefGoogle Scholar
  6. 6.
    Fuggetta MP, Alvino E, Tricarico M, D’Atri S, Pepponi R, Prete SP, Bonmassar E (2000) Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Anticancer Res 20(3A):1667–1672PubMedGoogle Scholar
  7. 7.
    Takeda T, Fukunaga K, Miyazawa K, Takahashi T, Takeda H, Takeda Y, Tanigawa K, Morisaki T, Yamamoto I, Hasegawa T (2008) Immuno-cellular therapy-basic and clinical study. Int J Hyperthermia. Gan To Kagaku Ryoho 35(12):2244–2246Google Scholar
  8. 8.
    Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, Aitini E, Fava S, Schieppati G, Pinotti G, Visini M, Ianniello G, Di BM (2002) In vitro effect of hyperthermia on natural cell-mediated cytotoxicity. Ann Oncol 13(2):299–307CrossRefGoogle Scholar
  9. 9.
    Dayanc BE, Beachy SH, Ostberg JR, Repasky EA (2008) Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses. Int J Hyperth 24(1):41–45CrossRefGoogle Scholar
  10. 10.
    Milani V, Noessner E (2006) Effects of thermal stress on tumor antigenicity and recognition by immune effector cells. Cancer Immunol Immunother 55(3):312–319CrossRefGoogle Scholar
  11. 11.
    Moseley P (2000, July 25) Stress proteins and the immune response. Immunopharmacology 48(3):299–302CrossRefGoogle Scholar
  12. 12.
    Anisimova NY, Kiselevskiy MV, Abdullaev AG, Malakhova NV, Sitdikova SM, Polotskiy BE, Davydov MM (2016) Effect of hyperthermia on the viability and proliferative activity of tumor cells. Russian Oncol J 21(5):250–252Google Scholar
  13. 13.
    Shubina IZ, Bliumenberg AG, Volkov SM, Demidov LV, Kiselevsky MV (2007) Adoptive immunotherapy of malignancies. Vestn Ross Akad Med Nauk 11:9–15Google Scholar
  14. 14.
    Shubina IZ, Titov KS, Mikhailova IN, Kiselevsky MV (2014) Looking into the future of immunotherapy or how to find Cinderella? Int J Cancer Prev 6(3–4):413–424Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Natalia Yu. Anisimova
    • 1
  • Irina Zh. Zhubina
    • 1
  • Fedor V. Donenko
    • 1
  • Julia I. Dolzhikova
    • 1
  • Antonina V. Kshnaykina
    • 1
  • Mikhail V. Kiselevskiy
    • 1
  1. 1.Laboratory of Cell ImmunityN.N. Blokhin National Medical Research CenterMoscowRussia

Personalised recommendations